Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 55

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 55
---
714)(36)%$16,567 $24,283 $(7,716)(32)%Spatial7,072 11,415 (4,343)(38)24,744 44,078 (19,334)(44)Total instruments revenue11,999 19,056 (7,057)(37)41,311 68,361 (27,050)(40)ConsumablesChromium92,519 96,536 (4,017)(4)262,416 274,571 (12,155)(4)Spatial35,373 29,668 5,705 19 103,017 85,330 17,687 21 Total consumables revenue127,892 126,204 1,688 1 365,433 359,901 5,532 2 Services8,128 6,299 1,829 29 24,255 17,292 6,963 40 Products and services revenue148,019 151,559 (3,540)(2)430,999 445,554 (14,555)(3)License and royalty revenue983 95 888 935 45,794 210 45,584 21707 Total revenue$149,002 $151,654 $(2,652)(2)%$476,793 $445,764 $31,029 7 %

Products and services revenue decreased $3.5 million, or 2%, to $148.0 million for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. Instruments revenue decreased $7.1 million, or 37%, to $12.0 million for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. Consumables revenue increased $1.7 million, or 1%, to $127.9 million for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. Services revenue increased $1.8 million, or 29%, to $8.1 million for the three months ended September 30, 2025 as compared to three months ended September 30, 2024, primarily driven by an increase in service plans for instruments coming off warranty. 

Products and services revenue